Eton Pharmaceuticals, Inc. (ETON) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 44 days, typically, give or take 18 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026after close 36 8-K
Q2 FY2026Thu, Aug 13, 2026after close 44 8-K
Q1 FY2026Thu, May 14, 2026after close 44 8-K
Q4 FY2025Thu, Mar 19, 2026after close 78 8-K
Q3 FY2025Thu, Nov 6, 2025after close 37 8-K
Q2 FY2025Thu, Aug 7, 2025after close 38 8-K
Q1 FY2025Tue, May 13, 2025after close 43 8-K
Q4 FY2024Tue, Mar 18, 2025before open 77 8-K

What they guided beta

Q3 FY2026 "Raised 2026 revenue guidance to more than $175 million, from prior guidance of more than $145 million; raised 2026 Adjusted EBITDA to more than 40%, from prior guidance of more than 35%" exhibit
Q3 FY2026 "We are raising both our revenue and adjusted EBITDA guidance for 2026, reflecting the strong momentum in our business,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals." exhibit
Q3 FY2026 "The Company expects continued organic growth from these products through the remainder of 2026 and beyond." exhibit
Q3 FY2026 "Licensed product candidate ASN-001 and initiated bioavailability study, with first participant expected to be dosed in January 2027." exhibit
Q3 FY2026 "With a bioavailability study underway, Eton anticipates submitting a New Drug Application (NDA) in 2027." exhibit
Q2 FY2026 "Raising full year revenue guidance, with 2026 revenue now expected to exceed $145 million, up from previous guidance of more than $120 million" exhibit
Q2 FY2026 "The Company plans to initiate a bioavailability study and anticipates a New Drug Application (“NDA”) submission upon the study’s completion in the second half of 2027." exhibit
Q2 FY2026 "The product is FDA-approved, and Eton expects to begin commercializing the product in September 2026." exhibit
Q2 FY2026 "The Company plans to initiate a bioavailability study for the product later this month and remains on track to submit an NDA by the end of 2026, allowing for potential approval and launch in 2027." exhibit
Q2 FY2026 "If pilot study results are successful, Eton anticipates initiating a pivotal clinical study in early 2027." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ETON
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ETON

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

ETON earnings date badge

HTML

<a href="https://veritasdata.dev/company/ETON/"><img src="https://veritasdata.dev/embed/ETON.svg" alt="ETON earnings date" width="240" height="56"></a>

Markdown

[![ETON earnings date](https://veritasdata.dev/embed/ETON.svg)](https://veritasdata.dev/company/ETON/)

Script

<script async src="https://veritasdata.dev/embed/ETON.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ETON"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.